Christopher Shen, M.D., joined Essex Woodlands in 2007 from New Enterprise Associates, a diversified venture capital fund, where he invested in biopharmaceutical and medical device companies. Prior to joining EWHV, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation's Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator.
Dr. Shen has been appointed Consulting Professor of Medicine at Stanford University, teaching courses on medical technology innovation. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his M.D. from the Stanford School of Medicine, his M.B.A. from Stanford Graduate School of Business, and an M.S. in Biomechanical Engineering from the Stanford School of Engineering. He received his B.S. in Biological Sciences from Stanford University. Dr. Shen currently is an observer on the boards of Oraya Therapeutics, Inc., Entellus Medical and Nellix Endovascular, Inc.
|
